These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22087174)

  • 41. [Oxidative stress and antioxidant defense in alcoholic liver disease and chronic hepatitis C].
    Pár A; Róth E; Rumi G; Kovács Z; Nemes J; Mózsik G
    Orv Hetil; 2000 Jul; 141(30):1655-9. PubMed ID: 10962902
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.
    Bizollon T; Palazzo U; Ducerf C; Chevallier M; Elliott M; Baulieux J; Pouyet M; Trepo C
    Hepatology; 1997 Aug; 26(2):500-4. PubMed ID: 9252166
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ribavirin induced hemolysis: a novel mechanism of action against chronic hepatitis C virus infection.
    Soota K; Maliakkal B
    World J Gastroenterol; 2014 Nov; 20(43):16184-90. PubMed ID: 25473172
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of Nigella sativa on outcome of hepatitis C in Egypt.
    Barakat EM; El Wakeel LM; Hagag RS
    World J Gastroenterol; 2013 Apr; 19(16):2529-36. PubMed ID: 23674855
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study.
    Harada N; Hiramatsu N; Oze T; Tatsumi T; Hayashi N; Takehara T
    J Med Virol; 2015 Jul; 87(7):1199-206. PubMed ID: 25772024
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
    Sagnelli E; Pisaturo M; Stanzione M; Messina V; Alessio L; Sagnelli C; Starace M; Pasquale G; Coppola N
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1174-1180.e11. PubMed ID: 23591280
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of SNPs in interferon receptor genes in chronic hepatitis C with response to combined therapy of interferon and ribavirin.
    Heidari Z; Shahzamani K; Ghanbari R; Tahamsebifar A
    Acta Med Iran; 2014; 52(10):740-7. PubMed ID: 25369007
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antioxidant supplementation for lung disease in cystic fibrosis.
    Ciofu O; Smith S; Lykkesfeldt J
    Cochrane Database Syst Rev; 2019 Oct; 10(10):CD007020. PubMed ID: 31580490
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antioxidant defense in patients with chronic viral hepatitis B and C type.
    Namiduru ES; Namiduru M; Tarakçioğlu M; Toy A
    Clin Lab; 2010; 56(5-6):207-13. PubMed ID: 20575468
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C.
    Gerotto M; Sullivan DG; Polyak SJ; Chemello L; Cavalletto L; Pontisso P; Alberti A; Gretch DR
    J Virol; 1999 Sep; 73(9):7241-7. PubMed ID: 10438811
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Future studies of combination therapy for chronic hepatitis C: optimizing response rates for each hepatitis C population.
    Main J
    J Hepatol; 1995; 23 Suppl 2():32-5; discussion 35-6. PubMed ID: 8720292
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients.
    Cotonat T; Quiroga JA; López-Alcorocho JM; Clouet R; Pardo M; Manzarbeitia F; Carreño V
    Hepatology; 2000 Feb; 31(2):502-6. PubMed ID: 10655277
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Blood serum glutathione alpha s-transferase (alpha GST) activity during antiviral therapy in patients with chronic hepatitis C.
    Mazur W; Gonciarz M; Kajdy M; Mazurek U; Jurzak M; Wilczok T; Gonciarz Z
    Med Sci Monit; 2003 Aug; 9 Suppl 3():44-8. PubMed ID: 15156612
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Oxidative stress in patients with chronic hepatitis B before and after interferon alpha-2b treatment].
    Fan YC; Wang K; Han LY; Li XH; Wang HM; Wang LY; Hou YD
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Mar; 21(1):23-5. PubMed ID: 17429526
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial.
    Sherman KE; Sjogren M; Creager RL; Damiano MA; Freeman S; Lewey S; Davis D; Root S; Weber FL; Ishak KG; Goodman ZD
    Hepatology; 1998 Apr; 27(4):1128-35. PubMed ID: 9537454
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial.
    Andreone P; Gramenzi A; Cursaro C; Sbolli G; Fiorino S; Di Giammarino L; Miniero R; D'Errico A; Gasbarrini G; Bernardi M
    J Hepatol; 1999 May; 30(5):788-93. PubMed ID: 10365803
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
    Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
    Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clastogenic factors in the plasma of children exposed at Chernobyl.
    Emerit I; Quastel M; Goldsmith J; Merkin L; Levy A; Cernjavski L; Alaoui-Youssefi A; Pogossian A; Riklis E
    Mutat Res; 1997 Jan; 373(1):47-54. PubMed ID: 9015152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.